Event Group
Event Groups are part of the Adverse Events Module within the Results Section. They provide a way to organize and summarize adverse event data by grouping related events together.
Each Event Group typically represents a category or class of adverse events and includes statistical information such as the number of participants affected and at risk for different event types: deaths, serious events, and other events.
Event Group path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Group
Event Group
Ignite Creation Date:
2025-12-26 @ 10:46 PM
Ignite Modification Date:
2025-12-26 @ 10:46 PM
NCT ID:
NCT01165112
Group ID:
EG000
Title:
Treatment (Chemotherapy and Monoclonal Antibody Therapy)
Description:
Patients receive bendamustine hydrochloride IV over 30-60 minutes on days 1 and 2, etoposide IV over 60 minutes on days 1-3, and carboplatin IV over 60 minutes on day 1. Patients with CD20+ T-cell lymphoma disease also receive rituximab IV on day 2 or 3. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity.
Bendamustine Hydrochloride: Given IV
Carboplatin: Given IV
Rituximab: Given IV
Etoposide: Given IV
Laboratory Biomarker Analysis: Correlative studies
Deaths Number Affected:
None
Deaths Number At Risk:
None
Serious Number Affected:
14
Serious Number At Risk:
48
Other Number Affected:
46
Other Number At Risk:
48
Study:
NCT01165112
Results Section:
NCT01165112
Adverse Events Module:
NCT01165112